Redx Pharma plc Redx presentations at AACR 2017
March 02 2017 - 2:50AM
RNS Non-Regulatory
TIDMREDX
Redx Pharma plc
02 March 2017
2 March 2017
AIM: REDX
REDX PHARMA PLC
("Redx" or "the Company" or "the Group")
Redx to present new scientific data at AACR 2017
Redx, the drug development company, is pleased to announce that
it will present two scientific posters at the American Association
for Cancer Research (AACR) Annual Meeting April 1-5, 2017, in
Washington D.C., USA.
Session Date April 5, 2017, 8:00 AM -12:00 PM Eastern
& Time Time
------------------ -------------------------------------------------------------
Session Title Enzymes and Hormones and Metabolism
in Tumor Immunity
------------------ -------------------------------------------------------------
Presentation Development of 2(nd) generation indoleamine
Title 2,3-dioxygenase 1 (IDO1) selective
inhibitors
------------------ -------------------------------------------------------------
Session Location Section 24
------------------ -------------------------------------------------------------
Abstract # 5581 / 13
------------------ -------------------------------------------------------------
First author Thomas Pesnot
------------------ -------------------------------------------------------------
Abstract online http://www.abstractsonline.com/pp8/#!/4292/presentation/6237
------------------ -------------------------------------------------------------
Session Date April 5, 2017, 8:00 AM -12:00 PM Eastern
& Time Time
------------------ -------------------------------------------------------------
Session Title Oncogenes and Tumor Suppressors as
Therapeutic Targets
------------------ -------------------------------------------------------------
Presentation Development of REDX05358, a novel
Title highly selective and potent pan RAF
inhibitor and a potential therapeutic
for BRAF and RAS tumors
------------------ -------------------------------------------------------------
Session Location Section 6
------------------ -------------------------------------------------------------
Abstract # 5160 / 3
------------------ -------------------------------------------------------------
First author Helen Mason
------------------ -------------------------------------------------------------
Abstract online http://www.abstractsonline.com/pp8/#!/4292/presentation/4116
------------------ -------------------------------------------------------------
Dr Neil Murray, CEO of Redx, said:
"We're delighted to present new scientific data on two of our
pre-clinical programs at the AACR meeting in April. As we are
moving closer to the clinic with our most advanced programs, the
Porcupine inhibitor RXC004 and the reversible BTK inhibitor RXC005,
we continue to look for novel opportunities in several therapeutic
classes in oncology and immunology.'
For further information, please contact:
Redx Pharma Plc
Neil Murray, Chief Executive T: +44 151
706 4747
Karl Hård, Head of Investor Relations T: +44 7491
& 651 406
Corporate Communications
Cantor Fitzgerald Europe (Nomad & Broker) T: +44 20
7894 7000
Phil Davies/ Michael Reynolds
About Redx Pharma Plc
Company website: Redxpharma.com
Redx is focused on the discovery and development of proprietary,
small molecule therapeutics to address areas of high, unmet medical
need, principally in cancer, infection and immunology, providing a
pipeline of assets to larger and emerging companies. By improving
the characteristics of existing drug classes to create highly
differentiated, novel, best-in-class drugs, Redx has already
established a broad portfolio of proprietary drug programs.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGRGDXISGBGRD
(END) Dow Jones Newswires
March 02, 2017 02:50 ET (07:50 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024